

# Adolescent and Young Adult Committee

Friday, April 5, 2024 | 9:00 AM – 11:00 AM PT

Room: Chiliwack / 402

## Agenda

- A. **Welcome** *Becky Johnson, MD*
- B. **Where are AYAs Treated?** *Melissa Beauchemin, PhD (virtual)*
- C. **Guest Speaker: Substance Use in AYA Oncology** *Karen Effinger, MD*
- D. **Guest speaker: What Should the SWOG AYA Committee Prioritize?**  
*Archie Bleyer, MD*
- E. **Trial Updates:**
  - **S1823** *A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors*  
*Craig Nichols, MD*
  - **CTSU/ANHL1931** *A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma*  
*Manali Kamdar, MD*
  - **S1826** *A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age  $\geq$  12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma*  
*Alex Herrera, MD*
  - **NCORP Pilot Grant “TALK TO ME: Tailored AYA Trial Messaging”**  
*Allison Rosen, MS*
- F. **Q&A and discussion** *Becky Johnson, MD*